BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 33932119)

  • 1. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
    Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.
    Prabhu VV; Madhukar NS; Gilvary C; Kline CLB; Oster S; El-Deiry WS; Elemento O; Doherty F; VanEngelenburg A; Durrant J; Tarapore RS; Deacon S; Charter N; Jung J; Park DM; Gilbert MR; Rusert J; Wechsler-Reya R; Arrillaga-Romany I; Batchelor TT; Wen PY; Oster W; Allen JE
    Clin Cancer Res; 2019 Apr; 25(7):2305-2313. PubMed ID: 30559168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells.
    Amoroso F; Glass K; Singh R; Liberal F; Steele RE; Maguire S; Tarapore R; Allen JE; Van Schaeybroeck S; Butterworth KT; Prise K; O'Sullivan JM; Jain S; Waugh DJ; Mills IG
    Sci Rep; 2021 Feb; 11(1):4252. PubMed ID: 33608585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
    Dasari VR; Carey DJ; Gogoi R
    BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D
    Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR
    Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells.
    Geiß C; Witzler C; Poschet G; Ruf W; Régnier-Vigouroux A
    Eur J Immunol; 2021 May; 51(5):1246-1261. PubMed ID: 33442873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microarray analysis reveals ONC201 mediated differential mechanisms of CHOP gene regulation in metastatic and nonmetastatic colorectal cancer cells.
    Al Madhoun A; Haddad D; Al Tarrah M; Jacob S; Al-Ali W; Nizam R; Miranda L; Al-Rashed F; Sindhu S; Ahmad R; Bitar MS; Al-Mulla F
    Sci Rep; 2021 Jun; 11(1):11893. PubMed ID: 34088951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
    Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.
    Tu YS; He J; Liu H; Lee HC; Wang H; Ishizawa J; Allen JE; Andreeff M; Orlowski RZ; Davis RE; Yang J
    Neoplasia; 2017 Oct; 19(10):772-780. PubMed ID: 28863346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
    Stringer-Reasor EM; Baker GM; Skor MN; Kocherginsky M; Lengyel E; Fleming GF; Conzen SD
    Gynecol Oncol; 2015 Sep; 138(3):656-62. PubMed ID: 26115975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer.
    McFadden M; Singh SK; Kinnel B; Varambally S; Singh R
    J Ovarian Res; 2023 Nov; 16(1):220. PubMed ID: 37990267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
    Yoshihara M; Kajiyama H; Yokoi A; Sugiyama M; Koya Y; Yamakita Y; Liu W; Nakamura K; Moriyama Y; Yasui H; Suzuki S; Yamamoto Y; Ricciardelli C; Nawa A; Shibata K; Kikkawa F
    Int J Cancer; 2020 Apr; 146(8):2268-2280. PubMed ID: 31904865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer.
    Farmaki E; Nath A; Emond R; Karimi KL; Grolmusz VK; Cosgrove PA; Bild AH
    Elife; 2023 Sep; 12():. PubMed ID: 37772709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
    Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
    Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
    Al Sawah E; Chen X; Marchion DC; Xiong Y; Ramirez IJ; Abbasi F; Bou Zgheib N; Chon HS; Wenham RM; Apte SM; Judson PL; Lancaster JM
    Gynecol Oncol; 2013 Oct; 131(1):207-12. PubMed ID: 23877012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.